Prognostic Factors and Construction of Nomogram Prediction Model of Lung Cancer Patients Using Clinical and Blood Laboratory Parameters

IF 2.7 4区 医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY OncoTargets and therapy Pub Date : 2024-02-21 DOI:10.2147/ott.s444396
Yamin Zhang, Wei Wan, Rui Shen, Bohao Zhang, Li Wang, Hongyi Zhang, Xiaoyue Ren, Jie Cui, Jinpeng Liu
{"title":"Prognostic Factors and Construction of Nomogram Prediction Model of Lung Cancer Patients Using Clinical and Blood Laboratory Parameters","authors":"Yamin Zhang, Wei Wan, Rui Shen, Bohao Zhang, Li Wang, Hongyi Zhang, Xiaoyue Ren, Jie Cui, Jinpeng Liu","doi":"10.2147/ott.s444396","DOIUrl":null,"url":null,"abstract":"<strong>Objective:</strong> This work aimed to explore the prognostic risk factors of lung cancer (LC) patients and establish a line chart prediction model.<br/><strong>Methods:</strong> A total of 322 LC patients were taken as the study subjects. They were randomly divided into a training set (n = 202) and a validation set (n = 120). Basic information and laboratory indicators were collected, and the progression-free survival (PFS) and overall survival (OS) were followed up. Single-factor and cyclooxygenase (COX) multivariate analyses were performed on the training set to construct a Nomogram prediction model, which was validated with 120 patients in the validation set, and Harrell’s consistency was analyzed.<br/><strong>Results:</strong> Single-factor analysis revealed significant differences in PFS (<em>P</em>&lt; 0.05) between genders, body mass index (BMI), carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), squamous cell carcinoma antigen (SCCA), treatment methods, treatment response evaluation, smoking status, presence of pericardial effusion, and programmed death ligand 1 (PD-L1) at 0 and 1– 50%. Significant differences in OS (<em>P</em>&lt; 0.05) were observed for age, tumor location, treatment methods, White blood cells (WBC), uric acid (UA), CA125, pro-gastrin-releasing peptide (ProGRP), SCCA, cytokeratin fragment 21 (CYFRA21), and smoking status. COX analysis identified male gender, progressive disease (PD) as treatment response, and SCCA &gt; 1.6 as risk factors for LC PFS. The consistency indices of the line chart models for predicting PFS and OS were 0.782 and 0.772, respectively.<br/><strong>Conclusion:</strong> Male gender, treatment response of PD, and SCCA &gt; 1.6 are independent risk factors affecting the survival of LC patients. The PFS line chart model demonstrates good concordance.<br/><br/><strong>Keywords:</strong> laboratory parameters, LC, nomogram prediction model, KM analysis, cox multivariate analysis<br/>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2024-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"OncoTargets and therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/ott.s444396","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: This work aimed to explore the prognostic risk factors of lung cancer (LC) patients and establish a line chart prediction model.
Methods: A total of 322 LC patients were taken as the study subjects. They were randomly divided into a training set (n = 202) and a validation set (n = 120). Basic information and laboratory indicators were collected, and the progression-free survival (PFS) and overall survival (OS) were followed up. Single-factor and cyclooxygenase (COX) multivariate analyses were performed on the training set to construct a Nomogram prediction model, which was validated with 120 patients in the validation set, and Harrell’s consistency was analyzed.
Results: Single-factor analysis revealed significant differences in PFS (P< 0.05) between genders, body mass index (BMI), carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), squamous cell carcinoma antigen (SCCA), treatment methods, treatment response evaluation, smoking status, presence of pericardial effusion, and programmed death ligand 1 (PD-L1) at 0 and 1– 50%. Significant differences in OS (P< 0.05) were observed for age, tumor location, treatment methods, White blood cells (WBC), uric acid (UA), CA125, pro-gastrin-releasing peptide (ProGRP), SCCA, cytokeratin fragment 21 (CYFRA21), and smoking status. COX analysis identified male gender, progressive disease (PD) as treatment response, and SCCA > 1.6 as risk factors for LC PFS. The consistency indices of the line chart models for predicting PFS and OS were 0.782 and 0.772, respectively.
Conclusion: Male gender, treatment response of PD, and SCCA > 1.6 are independent risk factors affecting the survival of LC patients. The PFS line chart model demonstrates good concordance.

Keywords: laboratory parameters, LC, nomogram prediction model, KM analysis, cox multivariate analysis
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
利用临床和血液实验室参数预测肺癌患者的预后因素并构建提名图预测模型
目的:本研究旨在探讨肺癌(LC)患者的预后风险因素,并建立线图预测模型:本研究旨在探讨肺癌患者的预后风险因素,并建立线图预测模型:方法:以 322 名肺癌患者为研究对象。方法:以 322 名肺癌患者为研究对象,随机分为训练集(202 人)和验证集(120 人)。收集基本信息和实验室指标,并跟踪无进展生存期(PFS)和总生存期(OS)。对训练集进行单因素和环氧化酶(COX)多变量分析,构建诺模预测模型,并在验证集的120名患者中进行验证,分析哈雷尔一致性:单因素分析显示,性别、体重指数(BMI)、癌胚抗原(CEA)、癌抗原125(CA125)、鳞状细胞癌抗原(SCCA)、治疗方法、治疗反应评估、吸烟状况、是否存在心包积液和程序性死亡配体1(PD-L1)在PFS(P< 0.05)上的差异在0%和1%-50%之间有显著性。在年龄、肿瘤位置、治疗方法、白细胞(WBC)、尿酸(UA)、CA125、促胃泌素释放肽(ProGRP)、SCCA、细胞角蛋白片段 21(CYFRA21)和吸烟状况方面,观察到 OS 存在显著差异(P< 0.05)。COX分析确定男性性别、疾病进展(PD)作为治疗反应以及SCCA > 1.6为LC PFS的风险因素。预测PFS和OS的线图模型的一致性指数分别为0.782和0.772:结论:男性性别、PD 治疗反应和 SCCA > 1.6 是影响 LC 患者生存的独立危险因素。关键词:实验室指标;LC;提名图预测模型;KM分析;Cox多变量分析
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
OncoTargets and therapy
OncoTargets and therapy BIOTECHNOLOGY & APPLIED MICROBIOLOGY-ONCOLOGY
CiteScore
9.70
自引率
0.00%
发文量
221
审稿时长
1 months
期刊介绍: OncoTargets and Therapy is an international, peer-reviewed journal focusing on molecular aspects of cancer research, that is, the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer. The journal is characterized by the rapid reporting of high-quality original research, basic science, reviews and evaluations, expert opinion and commentary that shed novel insight on a cancer or cancer subtype. Specific topics covered by the journal include: -Novel therapeutic targets and innovative agents -Novel therapeutic regimens for improved benefit and/or decreased side effects -Early stage clinical trials Further considerations when submitting to OncoTargets and Therapy: -Studies containing in vivo animal model data will be considered favorably. -Tissue microarray analyses will not be considered except in cases where they are supported by comprehensive biological studies involving multiple cell lines. -Biomarker association studies will be considered only when validated by comprehensive in vitro data and analysis of human tissue samples. -Studies utilizing publicly available data (e.g. GWAS/TCGA/GEO etc.) should add to the body of knowledge about a specific disease or relevant phenotype and must be validated using the authors’ own data through replication in an independent sample set and functional follow-up. -Bioinformatics studies must be validated using the authors’ own data through replication in an independent sample set and functional follow-up. -Single nucleotide polymorphism (SNP) studies will not be considered.
期刊最新文献
Cytotoxic Evaluation, Molecular Docking, Molecular Dynamics, and ADMET Prediction of Isolupalbigenin Isolated from Erythrina subumbrans (Hassk). Merr. (Fabaceae) Stem Bark: Unveiling Its Anticancer Efficacy. Pregnancy and Breast Cancer: A Challenge for the Multidisciplinary Team. A Single Center Experience and Narrative Review. LncRNA PTPRG-AS1 Promotes Breast Cancer Progression by Modulating the miR-4659a-3p/QPCT Axis. Erratum: Synergism from the Combination of Ulinastatin and Curcumin Offers Greater Inhibition against Colorectal Cancer Liver Metastases via Modulating Matrix Metalloproteinase-9 and E-Cadherin Expression [Corrigendum]. Therapeutic Strategies in Advanced Cervical Cancer Detection, Prevention and Treatment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1